Clinical outcomes, when matched at presentation, do not vary between adult-onset Henöch-Schönlein purpura nephritis and IgA nephropathy

Hyung Jung Oh, Song Vogue Ahn, Dong Eun Yoo, Seung Jun Kim, Dong Ho Shin, Mi Jung Lee, Hyoung Rae Kim, Jung Tak Park, Tae Hyun Yoo, Shin Wook Kang, Kyu Hun Choi, Seung Hyeok Han

Research output: Contribution to journalArticle

31 Citations (Scopus)

Abstract

Henöch-Schönlein purpura nephritis (HSPN) is considered a systemic form of immunoglobulin A nephropathy (IgAN). Although these are different pictures of a single disease, there are no studies directly comparing long-term outcomes of these two clinical entities. To clarify this, we studied 120 patients with biopsy-proven HSPN and 1070 patients with IgAN. The primary outcome was the composite of a doubling of baseline serum creatinine, end-stage renal disease, or death. Secondary outcomes included the individual renal outcomes or the rate of decline in estimated glomerular filtration rate. In the unmatched cohort, patients with HSPN had more vasculitic symptoms, more favorable histologic features, and were more commonly treated with steroids than patients with IgAN. The risk of reaching the primary outcome was significantly lower in HSPN patients than patients with IgAN (hazard ratio, 0.67). The 1:2 propensity score matching gave matched pairs of 89 patients with HSPN and 178 patients with IgAN, resulting in no differences in baseline conditions. In this matched cohort, there were no significant differences in reaching the primary and secondary outcomes between the two groups. Thus, after adjustment by propensity score matching, clinical outcomes did not differ between HSPN and IgAN, suggesting the two forms of the same disease have a similar prognosis.

Original languageEnglish
Pages (from-to)1304-1312
Number of pages9
JournalKidney International
Volume82
Issue number12
DOIs
Publication statusPublished - 2012 Dec 2

Fingerprint

Purpura
Nephritis
IGA Glomerulonephritis
Immunoglobulin A
Propensity Score
Glomerular Filtration Rate
Chronic Kidney Failure
Creatinine
Steroids
Kidney
Biopsy
Serum

All Science Journal Classification (ASJC) codes

  • Nephrology

Cite this

Oh, Hyung Jung ; Ahn, Song Vogue ; Yoo, Dong Eun ; Kim, Seung Jun ; Shin, Dong Ho ; Lee, Mi Jung ; Kim, Hyoung Rae ; Park, Jung Tak ; Yoo, Tae Hyun ; Kang, Shin Wook ; Choi, Kyu Hun ; Han, Seung Hyeok. / Clinical outcomes, when matched at presentation, do not vary between adult-onset Henöch-Schönlein purpura nephritis and IgA nephropathy. In: Kidney International. 2012 ; Vol. 82, No. 12. pp. 1304-1312.
@article{67356f6feb3c404cab9fcb8d4b39dc9b,
title = "Clinical outcomes, when matched at presentation, do not vary between adult-onset Hen{\"o}ch-Sch{\"o}nlein purpura nephritis and IgA nephropathy",
abstract = "Hen{\"o}ch-Sch{\"o}nlein purpura nephritis (HSPN) is considered a systemic form of immunoglobulin A nephropathy (IgAN). Although these are different pictures of a single disease, there are no studies directly comparing long-term outcomes of these two clinical entities. To clarify this, we studied 120 patients with biopsy-proven HSPN and 1070 patients with IgAN. The primary outcome was the composite of a doubling of baseline serum creatinine, end-stage renal disease, or death. Secondary outcomes included the individual renal outcomes or the rate of decline in estimated glomerular filtration rate. In the unmatched cohort, patients with HSPN had more vasculitic symptoms, more favorable histologic features, and were more commonly treated with steroids than patients with IgAN. The risk of reaching the primary outcome was significantly lower in HSPN patients than patients with IgAN (hazard ratio, 0.67). The 1:2 propensity score matching gave matched pairs of 89 patients with HSPN and 178 patients with IgAN, resulting in no differences in baseline conditions. In this matched cohort, there were no significant differences in reaching the primary and secondary outcomes between the two groups. Thus, after adjustment by propensity score matching, clinical outcomes did not differ between HSPN and IgAN, suggesting the two forms of the same disease have a similar prognosis.",
author = "Oh, {Hyung Jung} and Ahn, {Song Vogue} and Yoo, {Dong Eun} and Kim, {Seung Jun} and Shin, {Dong Ho} and Lee, {Mi Jung} and Kim, {Hyoung Rae} and Park, {Jung Tak} and Yoo, {Tae Hyun} and Kang, {Shin Wook} and Choi, {Kyu Hun} and Han, {Seung Hyeok}",
year = "2012",
month = "12",
day = "2",
doi = "10.1038/ki.2012.302",
language = "English",
volume = "82",
pages = "1304--1312",
journal = "Kidney International",
issn = "0085-2538",
publisher = "Nature Publishing Group",
number = "12",

}

Clinical outcomes, when matched at presentation, do not vary between adult-onset Henöch-Schönlein purpura nephritis and IgA nephropathy. / Oh, Hyung Jung; Ahn, Song Vogue; Yoo, Dong Eun; Kim, Seung Jun; Shin, Dong Ho; Lee, Mi Jung; Kim, Hyoung Rae; Park, Jung Tak; Yoo, Tae Hyun; Kang, Shin Wook; Choi, Kyu Hun; Han, Seung Hyeok.

In: Kidney International, Vol. 82, No. 12, 02.12.2012, p. 1304-1312.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Clinical outcomes, when matched at presentation, do not vary between adult-onset Henöch-Schönlein purpura nephritis and IgA nephropathy

AU - Oh, Hyung Jung

AU - Ahn, Song Vogue

AU - Yoo, Dong Eun

AU - Kim, Seung Jun

AU - Shin, Dong Ho

AU - Lee, Mi Jung

AU - Kim, Hyoung Rae

AU - Park, Jung Tak

AU - Yoo, Tae Hyun

AU - Kang, Shin Wook

AU - Choi, Kyu Hun

AU - Han, Seung Hyeok

PY - 2012/12/2

Y1 - 2012/12/2

N2 - Henöch-Schönlein purpura nephritis (HSPN) is considered a systemic form of immunoglobulin A nephropathy (IgAN). Although these are different pictures of a single disease, there are no studies directly comparing long-term outcomes of these two clinical entities. To clarify this, we studied 120 patients with biopsy-proven HSPN and 1070 patients with IgAN. The primary outcome was the composite of a doubling of baseline serum creatinine, end-stage renal disease, or death. Secondary outcomes included the individual renal outcomes or the rate of decline in estimated glomerular filtration rate. In the unmatched cohort, patients with HSPN had more vasculitic symptoms, more favorable histologic features, and were more commonly treated with steroids than patients with IgAN. The risk of reaching the primary outcome was significantly lower in HSPN patients than patients with IgAN (hazard ratio, 0.67). The 1:2 propensity score matching gave matched pairs of 89 patients with HSPN and 178 patients with IgAN, resulting in no differences in baseline conditions. In this matched cohort, there were no significant differences in reaching the primary and secondary outcomes between the two groups. Thus, after adjustment by propensity score matching, clinical outcomes did not differ between HSPN and IgAN, suggesting the two forms of the same disease have a similar prognosis.

AB - Henöch-Schönlein purpura nephritis (HSPN) is considered a systemic form of immunoglobulin A nephropathy (IgAN). Although these are different pictures of a single disease, there are no studies directly comparing long-term outcomes of these two clinical entities. To clarify this, we studied 120 patients with biopsy-proven HSPN and 1070 patients with IgAN. The primary outcome was the composite of a doubling of baseline serum creatinine, end-stage renal disease, or death. Secondary outcomes included the individual renal outcomes or the rate of decline in estimated glomerular filtration rate. In the unmatched cohort, patients with HSPN had more vasculitic symptoms, more favorable histologic features, and were more commonly treated with steroids than patients with IgAN. The risk of reaching the primary outcome was significantly lower in HSPN patients than patients with IgAN (hazard ratio, 0.67). The 1:2 propensity score matching gave matched pairs of 89 patients with HSPN and 178 patients with IgAN, resulting in no differences in baseline conditions. In this matched cohort, there were no significant differences in reaching the primary and secondary outcomes between the two groups. Thus, after adjustment by propensity score matching, clinical outcomes did not differ between HSPN and IgAN, suggesting the two forms of the same disease have a similar prognosis.

UR - http://www.scopus.com/inward/record.url?scp=84870582400&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84870582400&partnerID=8YFLogxK

U2 - 10.1038/ki.2012.302

DO - 10.1038/ki.2012.302

M3 - Article

C2 - 22895518

AN - SCOPUS:84870582400

VL - 82

SP - 1304

EP - 1312

JO - Kidney International

JF - Kidney International

SN - 0085-2538

IS - 12

ER -